$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

$abeo Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031150 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue			$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.404M	$8.646M	$5.830M
YoY Change	53.94%	72.2%	2.6%
% of Gross Profit
Research & Development	$8.941M	$9.218M	$7.379M
YoY Change	25.08%	8.15%	17.65%
% of Gross Profit
Depreciation & Amortization	$487.0K	$487.0K	$491.0K
YoY Change	-6.35%	-20.81%	-32.65%
% of Gross Profit
Operating Expenses	$15.35M	$17.86M	$13.21M
YoY Change	35.39%	18.16%	9.58%
Operating Profit	-$15.35M	-$17.86M
YoY Change	35.39%	69.26%
Interest Expense	$1.102M	$1.072M	$634.0K
YoY Change	949.52%	241.4%	322.67%
% of Operating Profit
Other Income/Expense, Net	$145.0K	$224.0K	-$4.016M
YoY Change	30.63%	-103.49%	-134.44%
Pretax Income	-$30.27M	$7.406M	-$16.59M
YoY Change	155.65%	-144.47%	1373.45%
Income Tax
% Of Pretax Income
Net Earnings	-$30.27M	$7.406M	-$16.59M
YoY Change	155.74%	-144.47%	1373.45%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.63	$0.19
Diluted Earnings Per Share	-$0.63	-$0.26	-$0.65
COMMON SHARES
Basic Shares Outstanding	43.31M shares	41.19M shares	24.77M shares
Diluted Shares Outstanding	48.08M shares	51.23M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$109.7M	$122.7M	$52.23M
YoY Change	103.91%	233.7%	0.15%
Cash & Equivalents	$15.73M	$34.43M	$14.47M
Short-Term Investments	$93.98M	$88.28M	$37.75M
Other Short-Term Assets	$1.343M	$1.556M	$1.067M
YoY Change	3.31%	1.1%	40.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$1.613M	$1.640M	$2.444M
Total Short-Term Assets	$112.7M	$125.9M	$55.74M
YoY Change	96.73%	185.9%	4.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.058M	$3.975M	$3.533M
YoY Change	1.48%	-57.73%	-38.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$88.00K	$100.0K	$277.0K
YoY Change	-12.0%	-7.41%	544.19%
Total Long-Term Assets	$7.935M	$8.099M	$8.265M
YoY Change	-10.06%	-14.85%	-25.64%
TOTAL ASSETS
Total Short-Term Assets	$112.7M	$125.9M	$55.74M
Total Long-Term Assets	$7.935M	$8.099M	$8.265M
Total Assets	$120.6M	$134.0M	$64.00M
YoY Change	82.47%	150.24%	-0.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.789M	$3.099M	$1.858M
YoY Change	7.6%	-10.87%	2.6%
Accrued Expenses	$5.210M	$4.924M	$5.985M
YoY Change	31.17%	-14.48%	49.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.444M	$2.222M
YoY Change
Total Short-Term Liabilities	$18.42M	$16.84M	$13.42M
YoY Change	119.0%	78.42%	72.54%
LONG-TERM LIABILITIES
Long-Term Debt	$14.21M	$16.13M	$0.00
YoY Change
Other Long-Term Liabilities	$42.19M	$27.79M	$35.75M
YoY Change	18.51%	-20.07%
Total Long-Term Liabilities	$14.21M	$16.13M	$35.75M
YoY Change	-60.1%	-53.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.42M	$16.84M	$13.42M
Total Long-Term Liabilities	$14.21M	$16.13M	$35.75M
Total Liabilities	$74.82M	$60.76M	$49.18M
YoY Change	69.85%	37.46%	31.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$804.0M	-$773.7M	-$749.5M
YoY Change	9.7%	7.29%	7.79%
Common Stock	$434.0K	$417.0K	$265.0K
YoY Change	75.71%	93.95%	-96.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.77M	$73.24M	$14.83M
YoY Change
Total Liabilities & Shareholders Equity	$120.6M	$134.0M	$64.00M
YoY Change	82.47%	150.24%	-0.33%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$30.27M	$7.406M	-$16.59M
YoY Change	155.74%	-144.47%	1373.45%
Depreciation, Depletion And Amortization	$487.0K	$487.0K	$491.0K
YoY Change	-6.35%	-20.81%	-32.65%
Cash From Operating Activities	-$12.23M	-$12.68M	-$9.235M
YoY Change	113.14%	23.34%	-34.0%
INVESTING ACTIVITIES
Capital Expenditures	$404.0K	$711.0K	$37.00K
YoY Change	910.0%	2121.88%	48.0%
Acquisitions
YoY Change
Other Investing Activities	-$5.763M	-$43.42M	$11.57M
YoY Change	-69.18%	-928.17%	-145.78%
Cash From Investing Activities	-$6.167M	-$44.13M	$11.53M
YoY Change	-67.09%	-946.9%	-145.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-299.0K	73.68M	7.467M
YoY Change	-101.3%	1013.39%	-82.54%
NET CHANGE
Cash From Operating Activities	-12.23M	-12.68M	-9.235M
Cash From Investing Activities	-6.167M	-44.13M	11.53M
Cash From Financing Activities	-299.0K	73.68M	7.467M
Net Change In Cash	-18.70M	16.87M	9.761M
YoY Change	1146.67%	991.78%	180.17%
FREE CASH FLOW
Cash From Operating Activities	-$12.23M	-$12.68M	-$9.235M
Capital Expenditures	$404.0K	$711.0K	$37.00K
Free Cash Flow	-$12.64M	-$13.40M	-$9.272M
YoY Change	118.65%	29.85%	-33.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6000000.0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
	ABEO	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue	3900000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6000000.0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
	ABEO	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue	3900000	usd
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities		usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q2	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q2	us-gaap	Royalty Expense RoyaltyExpense		usd
	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2024Q2	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets		usd
	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets		usd
CY2024Q2	ABEO	Stock Issued During Period Value Of Common Stock Upon Exercise Of Prefunded Warrants Net Of Shares Settled StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled		usd
	ABEO	Stock Issued During Period Value Of Common Stock Upon Exercise Of Prefunded Warrants Net Of Shares Settled StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled		usd
	ABEO	Noncash Gain Of Right Of Use Lease Assets NoncashGainOfRightOfUseLeaseAssets		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
	ABEO	Proceeds From Underwritten Sales Of Common Stock Net Of Issuance Costs ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities		usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q2	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q2	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2024Q2	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets		usd
	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets		usd
CY2024Q2	ABEO	Stock Issued During Period Value Of Common Stock Upon Exercise Of Prefunded Warrants Net Of Shares Settled StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled		usd
	ABEO	Noncash Gain Of Right Of Use Lease Assets NoncashGainOfRightOfUseLeaseAssets		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
	ABEO	Proceeds From Underwritten Sales Of Common Stock Net Of Issuance Costs ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities		usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q2	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Entity File Number EntityFileNumber	001-15771
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities		usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q2	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities		usd
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cleveland
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
	dei	City Area Code CityAreaCode	(646)
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2023Q4	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15771
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-0221517
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6555 Carnegie Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	4thFloor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cleveland
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	813-4701
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14473000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	37753000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2444000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	729000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	55737000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1858000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q2	ABEO	Due To Licensor DueToLicensor	4805000	usd
CY2023Q4	ABEO	Due To Licensor DueToLicensor	4580000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13422000	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	668000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	60762000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	49176000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2023Q4	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15771
	dei	Entity Registrant Name EntityRegistrantName	ABEONA THERAPEUTICS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-0221517
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6555 Carnegie Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	4thFloor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cleveland
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	44103
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	813-4701
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	ABEO	Due To Licensor DueToLicensor	4805000	usd
CY2023Q4	ABEO	Due To Licensor DueToLicensor	4580000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	338000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2444000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	729000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	55737000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4455000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277000	usd
CY2023Q4	us-gaap	Assets Assets	64002000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1858000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16843000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13422000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-0221517
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6555 Carnegie Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cleveland
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	44103
	dei	Local Phone Number LocalPhoneNumber	813-4701
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
	dei	Trading Symbol TradingSymbol	ABEO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14473000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	37753000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	338000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2444000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	729000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	55737000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4455000	usd
CY2023Q4	us-gaap	Assets Assets	64002000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1858000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2023Q4	ABEO	Due To Licensor DueToLicensor	4580000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16843000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13422000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	60762000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	49176000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
	dei	Trading Symbol TradingSymbol	ABEO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43314397	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14473000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	37753000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	729000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2023Q4	us-gaap	Assets Assets	64002000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1858000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
CY2024Q2	ABEO	Due To Licensor DueToLicensor	4805000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16843000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13422000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16133000	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	668000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	60762000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	49176000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	265000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	764151000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773696000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-749524000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-66000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64002000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
	us-gaap	Royalty Expense RoyaltyExpense	1575000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9218000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8523000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	60762000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	49176000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26523878	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26523878	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	265000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	846654000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-749524000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134003000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
	us-gaap	Royalty Expense RoyaltyExpense	1575000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9218000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8523000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16425000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16564000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8646000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5021000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9018000	usd
CY2023Q2	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	17864000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	14054000	usd
	us-gaap	Operating Expenses OperatingExpenses	32194000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17864000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32194000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22592000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	417000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	781000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	103000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8629000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6364000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2215000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	386000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2618000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26523878	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26523878	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	417000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	265000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	846654000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	764151000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773696000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-749524000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-66000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134003000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
CY2023Q2	us-gaap	Royalty Expense RoyaltyExpense	1575000	usd
	us-gaap	Royalty Expense RoyaltyExpense	1575000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9218000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8523000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16425000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16564000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5021000	usd
CY2023Q2	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	17864000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	14054000	usd
	us-gaap	Operating Expenses OperatingExpenses	32194000	usd
	us-gaap	Operating Expenses OperatingExpenses	26092000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17864000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10554000	usd
CY2024Q2	us-gaap	Interest Income Operating InterestIncomeOperating	1191000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	417000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	781000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	1072000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	103000	usd
	us-gaap	Interest Expense InterestExpense	2024000	usd
	us-gaap	Interest Expense InterestExpense	204000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2215000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	386000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2618000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	417000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	265000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	846654000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-749524000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-66000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134003000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64002000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
CY2023Q2	us-gaap	Royalty Expense RoyaltyExpense	1575000	usd
	us-gaap	Royalty Expense RoyaltyExpense	1575000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9218000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8523000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16425000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16564000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8646000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5021000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15769000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9018000	usd
CY2023Q2	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	17864000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	14054000	usd
	us-gaap	Operating Expenses OperatingExpenses	32194000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32194000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22592000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	417000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	781000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	1072000	usd
	us-gaap	Interest Expense InterestExpense	204000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2215000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	386000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2618000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40010481	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33662908	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16425000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16564000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15769000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9018000	usd
CY2023Q2	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
	ABEO	Gain Loss On Rightofuse Lease Assets GainLossOnRightofuseLeaseAssets	1065000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	17864000	usd
	us-gaap	Operating Expenses OperatingExpenses	32194000	usd
	us-gaap	Operating Expenses OperatingExpenses	26092000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17864000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10554000	usd
CY2024Q2	us-gaap	Interest Income Operating InterestIncomeOperating	1191000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	417000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	2034000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	781000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	1072000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	103000	usd
	us-gaap	Interest Expense InterestExpense	2024000	usd
	us-gaap	Interest Expense InterestExpense	204000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-24927000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8629000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6364000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2215000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	386000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2618000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40010481	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18017874	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33662908	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51226715	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18017874	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	50000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-30000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-68000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7456000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16684000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25727000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18017874	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33662908	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17464026	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51226715	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18017874	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	50000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-30000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-68000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	34000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7456000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16684000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24240000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25727000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-8881000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1323000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-315000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3505000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70153000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	50000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2869000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-329000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9962000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70153000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-68000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18740000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	927000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-5000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6367000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-9000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6623000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	34000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40010481	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18017874	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17464026	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	50000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-30000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-68000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	34000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7456000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16684000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24240000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25727000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-8881000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-315000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3505000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70153000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	50000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2869000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-329000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9962000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70153000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	927000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-5000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6367000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-9000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6623000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	978000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1276000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2869000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1697000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6364000	usd
	ABEO	Noncash Gain Of Right Of Use Lease Assets NoncashGainOfRightOfUseLeaseAssets	1065000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	66000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	450000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17464026	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18017874	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-30000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	34000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7456000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16684000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-8881000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1323000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	50000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2869000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9962000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	73241000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18740000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	927000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-5000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6367000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1697000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-9000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6623000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	34000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	978000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1276000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2869000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1697000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
	ABEO	Noncash Gain Of Right Of Use Lease Assets NoncashGainOfRightOfUseLeaseAssets	1065000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	431000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	450000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	735000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	204000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3500000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-804000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-121000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-590000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27222000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89890000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	39359000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	50000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2869000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70153000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-5000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6367000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1697000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-9000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6623000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	978000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1276000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2869000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6364000	usd
	ABEO	Noncash Gain Of Right Of Use Lease Assets NoncashGainOfRightOfUseLeaseAssets	1065000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	66000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	74000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	450000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	735000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	204000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3500000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-804000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	639000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-177000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-590000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27222000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	250000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	179000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89890000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	14156000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	39359000	usd
	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-28000	usd
	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-9000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	20000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19953000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	978000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2869000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1697000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7626000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6364000	usd
	ABEO	Noncash Gain Of Right Of Use Lease Assets NoncashGainOfRightOfUseLeaseAssets	1065000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	66000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	450000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	735000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	204000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3500000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-804000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-177000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-121000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-590000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-622000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22028000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1436000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	179000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89890000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	14156000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	39359000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	21649000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51949000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7422000	usd
	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-28000	usd
	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-9000	usd
	ABEO	Proceeds From Underwritten Sales Of Common Stock Net Of Issuance Costs ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts	70153000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	20000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19953000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7992000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14811000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14555000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34426000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6225000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6563000	usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement	1042000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1290000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	735000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3500000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-804000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	65000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-121000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-590000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27222000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1436000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	250000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	179000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89890000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	14156000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	39359000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7422000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9962000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6623000	usd
	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-28000	usd
	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-9000	usd
	ABEO	Proceeds From Underwritten Sales Of Common Stock Net Of Issuance Costs ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts	70153000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	963000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	99124000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6614000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19953000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7992000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14811000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34764000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34426000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6225000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34764000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6563000	usd
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities	419000	usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement	1042000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1290000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51949000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9962000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19953000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7992000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14811000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14555000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34764000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6563000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34426000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6225000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6563000	usd
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities	419000	usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement	1042000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1290000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25800000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_ztsUNVKmLrm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Other Receivables OtherReceivables	1600000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	2100000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7992000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14555000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34426000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6225000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6563000	usd
	ABEO	Rightofuse Lease Assets Obtained From New Operating Lease Liabilities RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities	419000	usd
	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement	1042000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1290000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25800000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_ztsUNVKmLrm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25800000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_ztsUNVKmLrm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Other Receivables OtherReceivables	1600000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773700000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	123000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_ztsUNVKmLrm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Other Receivables OtherReceivables	1600000	usd
CY2024Q2	us-gaap	Other Receivables OtherReceivables	1600000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	2100000	usd
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13448000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16654000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24172000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25761000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	40010481000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	18017874000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	17464026000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	178931000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	2293570000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8165236000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	578497000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18017874	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33662908	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13448000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16654000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24172000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25761000	usd
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33662908000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	17464026000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	2293570000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8165236000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	578497000	shares
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11216234000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51226715	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33662908	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1788000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12428336	shares
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	37819000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	37753000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13448000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16654000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	40010481000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	18017874000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33662908000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	17464026000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	178931000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	2293570000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8165236000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	578497000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51226715	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18017874	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12194905	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12428336	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12194905	shares
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	88416000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	88282000	usd
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	66000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	7406000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24172000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25761000	usd
CY2024Q2	ABEO	Fair Value Adjustments For Warrant And Derivative Liabilities FairValueAdjustmentsForWarrantAndDerivativeLiabilities	-20854000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13448000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24172000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25761000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	40010481000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	18017874000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33662908000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	17464026000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	178931000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	2293570000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	578497000	shares
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11216234000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51226715	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18017874	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33662908	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17464026	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1788000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12428336	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12194905	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1788000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12194905	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12194905	shares
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	88416000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	134000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	88282000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	37819000	usd
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	66000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	37753000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16524000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1000000.0	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
	ABEO	Fair Value Adjustment Of Warrants Issued FairValueAdjustmentOfWarrantsIssued	220000	usd
	ABEO	Gain Loss Recognized In Earnings From Change In Fair Value GainLossRecognizedInEarningsFromChangeInFairValue	-7472000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	88416000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	134000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	88282000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	37819000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17941000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16524000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12991000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3975000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
	ABEO	Fair Value Adjustment Of Warrants Issued FairValueAdjustmentOfWarrantsIssued	220000	usd
	ABEO	Gain Loss Recognized In Earnings From Change In Fair Value GainLossRecognizedInEarningsFromChangeInFairValue	-7472000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16524000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13966000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12991000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3975000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1000000.0	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
	ABEO	Fair Value Adjustment Of Warrants Issued FairValueAdjustmentOfWarrantsIssued	220000	usd
	ABEO	Gain Loss Recognized In Earnings From Change In Fair Value GainLossRecognizedInEarningsFromChangeInFairValue	-7472000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
	ABEO	Fair Value Of Derivatives Issued FairValueOfDerivativesIssued	822000	usd
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	154000	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	668000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16524000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13966000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12991000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
	ABEO	Fair Value Adjustment Of Warrants Issued FairValueAdjustmentOfWarrantsIssued	220000	usd
	ABEO	Gain Loss Recognized In Earnings From Change In Fair Value GainLossRecognizedInEarningsFromChangeInFairValue	-7472000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
	ABEO	Fair Value Of Derivatives Issued FairValueOfDerivativesIssued	822000	usd
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	154000	usd
CY2024Q2	ABEO	Warrant Liabilities WarrantLiabilities	24100000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zdLzAl0MTzIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82E_zoOEhfm6gxs">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zTeHB79hTVu" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zywLcCN2aBa7" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zS12qY4LlHa3" title="Effective interest rate stated percentage">9.6</span>%. The present value of the amount due in November 2024 was $<span id="xdx_909_eus-gaap--LongTermDebt_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zGReeumW4O59" title="Long term debt">4.8</span> million and $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_ziqDW0dKeXPa" title="Long term debt">4.6</span> million as of June 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	ABEO	Fair Value Of Derivatives Issued FairValueOfDerivativesIssued	822000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zdLzAl0MTzIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82E_zoOEhfm6gxs">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zTeHB79hTVu" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zywLcCN2aBa7" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zS12qY4LlHa3" title="Effective interest rate stated percentage">9.6</span>%. The present value of the amount due in November 2024 was $<span id="xdx_909_eus-gaap--LongTermDebt_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zGReeumW4O59" title="Long term debt">4.8</span> million and $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_ziqDW0dKeXPa" title="Long term debt">4.6</span> million as of June 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3423000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3688000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2297000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4924000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zdLzAl0MTzIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82E_zoOEhfm6gxs">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zTeHB79hTVu" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zywLcCN2aBa7" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zS12qY4LlHa3" title="Effective interest rate stated percentage">9.6</span>%. The present value of the amount due in November 2024 was $<span id="xdx_909_eus-gaap--LongTermDebt_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zGReeumW4O59" title="Long term debt">4.8</span> million and $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_ziqDW0dKeXPa" title="Long term debt">4.6</span> million as of June 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3423000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2297000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4924000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zdLzAl0MTzIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82E_zoOEhfm6gxs">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zTeHB79hTVu" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zywLcCN2aBa7" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zS12qY4LlHa3" title="Effective interest rate stated percentage">9.6</span>%. The present value of the amount due in November 2024 was $<span id="xdx_909_eus-gaap--LongTermDebt_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zGReeumW4O59" title="Long term debt">4.8</span> million and $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_ziqDW0dKeXPa" title="Long term debt">4.6</span> million as of June 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3423000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3688000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1501000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2297000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4924000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5400000	usd
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3423000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3688000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4924000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1792000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4810000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5400000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	328000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	662000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	708000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	122000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	116000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	196000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	215000	usd
CY2024Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	31000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	461000	usd
	us-gaap	Lease Cost LeaseCost	892000	usd
	us-gaap	Lease Cost LeaseCost	954000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5400000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	662000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	122000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	116000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	196000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	215000	usd
CY2024Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	461000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	482000	usd
	us-gaap	Lease Cost LeaseCost	892000	usd
	us-gaap	Lease Cost LeaseCost	954000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	886000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	791000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	807000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	823000	usd
CY2024Q2	ABEO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1693000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1043000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4810000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P62M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072	pure
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Remainder Of Fiscal Year FutureCashReceiptsFromOperatingSubleaseRemainderOfFiscalYear	319000	usd
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Next Twelve Months FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths	485000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2024Q2	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee	162000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5400000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	662000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	708000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	116000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	196000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	215000	usd
CY2024Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	34000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	31000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	461000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	482000	usd
	us-gaap	Lease Cost LeaseCost	892000	usd
	us-gaap	Lease Cost LeaseCost	954000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	886000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	791000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	807000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	823000	usd
CY2024Q2	ABEO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1693000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1043000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4810000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P62M
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	662000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	708000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	122000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	116000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	196000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	215000	usd
CY2024Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	461000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	482000	usd
	us-gaap	Lease Cost LeaseCost	892000	usd
	us-gaap	Lease Cost LeaseCost	954000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	886000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	791000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	807000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	823000	usd
CY2024Q2	ABEO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1693000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1043000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4810000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P62M
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Next Twelve Months FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths	485000	usd
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease FutureCashReceiptsFromOperatingSublease	804000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2024Q2	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee	162000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	886000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	791000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	807000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	823000	usd
CY2024Q2	ABEO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1693000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5853000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1043000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4810000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P62M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072	pure
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Remainder Of Fiscal Year FutureCashReceiptsFromOperatingSubleaseRemainderOfFiscalYear	319000	usd
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Next Twelve Months FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths	485000	usd
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease FutureCashReceiptsFromOperatingSublease	804000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1807000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	18355000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16133000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072	pure
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Remainder Of Fiscal Year FutureCashReceiptsFromOperatingSubleaseRemainderOfFiscalYear	319000	usd
CY2024Q2	ABEO	Future Cash Receipts From Operating Sublease Next Twelve Months FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths	485000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2024Q2	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee	162000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	18355000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16133000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6667000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4444000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2021Q4	ABEO	Fair Value Warrant Liabilities FairValueWarrantLiabilities	9000000.0	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1807000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16133000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6667000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7000000.0	usd
CY2021Q4	ABEO	Fair Value Warrant Liabilities FairValueWarrantLiabilities	9000000.0	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1323000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	927000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2869000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1697000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	179001	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M28D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	27279	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	37.85
	ABEO	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1	P7Y10D
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	18355000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2222000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16133000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6667000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8889000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4444000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7000000.0	usd
CY2021Q4	ABEO	Fair Value Warrant Liabilities FairValueWarrantLiabilities	9000000.0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2869000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1697000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	179001	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	178859	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	151580	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M28D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	27279	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	37.85
	ABEO	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1	P7Y10D
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6667000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8889000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4444000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2021Q4	ABEO	Fair Value Warrant Liabilities FairValueWarrantLiabilities	9000000.0	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1323000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1697000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	179001	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	43.71
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	178859	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M14D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	151580	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	38.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M28D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1000	usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	27279	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	37.85
	ABEO	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1	P7Y10D
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6000000.0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
	ABEO	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue	3900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2869000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1697000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	179001	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M29D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	142	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	43.71
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	178859	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	151580	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	38.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M28D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	27279	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	37.85
	ABEO	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1	P7Y10D
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6000000.0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
	ABEO	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue	3900000	usd

Files In Submission

Name	View Source	Status
0001493152-24-031150-index-headers.html	Edgar Link	pending
0001493152-24-031150-index.html	Edgar Link	pending
0001493152-24-031150.txt	Edgar Link	pending
0001493152-24-031150-xbrl.zip	Edgar Link	pending
abeo-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
abeo-20240630_def.xml	Edgar Link	unprocessable
abeo-20240630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
0001493152-24-031150-index-headers.html	Edgar Link	pending
0001493152-24-031150-index.html	Edgar Link	pending
0001493152-24-031150.txt	Edgar Link	pending
0001493152-24-031150-xbrl.zip	Edgar Link	pending
abeo-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
abeo-20240630_def.xml	Edgar Link	unprocessable
abeo-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abeo-20240630_cal.xml	Edgar Link	unprocessable
abeo-20240630_cal.xml	Edgar Link	unprocessable
abeo-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abeo-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

2024 Q3 Form 10-Q Financial Statement

#000149315224031150 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO ABEONA THERAPEUTICS INC. Stock $abeo

2024 Q3 Form 10-Q Financial Statement

#000149315224031150 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo